GAM Holding AG raised its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 182.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,567 shares of the medical research company’s stock after acquiring an additional 5,537 shares during the quarter. GAM Holding AG’s holdings in Iqvia were worth $1,111,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Cutler Group LP boosted its position in shares of Iqvia by 173.3% during the 2nd quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock worth $109,000 after acquiring an additional 2,600 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Iqvia by 177.2% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,156 shares of the medical research company’s stock worth $150,000 after acquiring an additional 739 shares in the last quarter. Fort L.P. acquired a new position in shares of Iqvia during the 2nd quarter worth about $118,000. Quad Cities Investment Group LLC acquired a new position in shares of Iqvia during the 2nd quarter worth about $140,000. Finally, Bessemer Group Inc. lifted its holdings in shares of Iqvia by 7,985.7% in the 3rd quarter. Bessemer Group Inc. now owns 1,698 shares of the medical research company’s stock valued at $220,000 after purchasing an additional 1,677 shares during the last quarter. 89.33% of the stock is owned by institutional investors and hedge funds.
IQV has been the subject of several research reports. Robert W. Baird boosted their target price on Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a report on Tuesday, October 2nd. Barclays boosted their target price on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Royal Bank of Canada boosted their target price on Iqvia to $137.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Raymond James boosted their target price on Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a report on Friday, August 31st. Finally, Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $134.41.
In other news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of the stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total transaction of $391,498,083.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of the stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total value of $442,118,987.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,117,903 shares of company stock valued at $881,082,166. 6.00% of the stock is owned by company insiders.
IQV opened at $117.98 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. The company has a market cap of $24.38 billion, a price-to-earnings ratio of 24.03, a P/E/G ratio of 1.75 and a beta of 0.81. Iqvia Holdings Inc has a 52 week low of $91.57 and a 52 week high of $135.48.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.03. The firm had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts expect that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “GAM Holding AG Has $1.11 Million Stake in Iqvia Holdings Inc (IQV)” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/12/08/gam-holding-ag-has-1-11-million-stake-in-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Further Reading: What is a capital gain?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.